Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Bacteroidetes or Bifidobacterium can reduce the risk of colitis during ipilimumab therapy by inhibiting pro-inflammatory cytokines.
Ipilimumab is associated with new-onset, immune-mediated colitis in about 30% of pazients
see also:
Adverse Events / Safety & Ipilimumab
[Bifidobacterium / Bifidobacter & Immune Checkpoi…